Key Segmentation:
By Product
-
Lutetium-177 Vipivotide Tetraxetan
-
Lutetium-177 Dotatate
-
Radium-223 Dichloride
-
Iobenguane I-131
-
Others
By Indication
-
Prostate Cancer
-
Neuroendocrine Tumors
-
Thyroid Cancer
-
Others
By Target Receptor
-
PSMA
-
SSTR
-
Others
By End User
-
Hospitals & Specialized Cancer Centers
-
Diagnostic & Imaging Centers
-
Academic & Research Institutes
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company's specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Indication)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Radioligand Therapy Market is expected to grow at a CAGR of 18.2% from 2026 to 2035
The Radioligand Therapy Market was valued at USD 2.98 Billion in 2025.
The market is driven by rising prostate cancer and neuroendocrine tumor prevalence, growing clinical validation of PSMA- and SSTR-targeted radioligand agents, and continued advancement of isotope production infrastructure.
The Prostate Cancer segment dominated the Radioligand Therapy Market in 2025, accounting for approximately 58.40% market share.
The North America region dominated the Radioligand Therapy Market in 2025, holding an 80.50% market share, driven by mature theranostics infrastructure and favorable reimbursement pathways.